FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Meta's Q3 profit slashed by a $15.93B tax charge, but the company remains focused on AI investment and expansion.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Meta's Q3 profit slashed by a $15.93B tax charge, but the company remains focused on AI investment and expansion.